1. Multimodality treatment of osteosarcoma: Radiation in a high-risk cohort
- Author
-
Christopher E. Pelloski, Cynthia E. Herzog, Pete Anderson, Winston W. Huh, Anita Mahajan, Eric L. Chang, Shiao Y. Woo, Dennis P.M. Hughes, and David G. Kornguth
- Subjects
Adult ,Male ,Adolescent ,medicine.medical_treatment ,Bone Neoplasms ,Multimodality Therapy ,Medical Records ,Metastasis ,Cohort Studies ,Risk Factors ,Antineoplastic Combined Chemotherapy Protocols ,Humans ,Medicine ,Ifosfamide ,Child ,Survival rate ,Etoposide ,Retrospective Studies ,Osteosarcoma ,Chemotherapy ,business.industry ,Radiotherapy Dosage ,Hematology ,medicine.disease ,Combined Modality Therapy ,Survival Rate ,Radiation therapy ,Methotrexate ,Unresectable Osteosarcoma ,Oncology ,Doxorubicin ,Pediatrics, Perinatology and Child Health ,Female ,Cisplatin ,Neoplasm Recurrence, Local ,business ,Nuclear medicine ,Follow-Up Studies ,medicine.drug - Abstract
Purpose Chemotherapy during radiation and/or bone-seeking radioisotope therapy (153-samarium; 1 mCi/kg) during radiation may improve osteosarcoma cancer control. Patients and Methods We analyzed our preliminary radiation experience in high-risk, metastatic, and/or recurrent patients during a consecutive period of 20 months (May 2005–December 2006). Results Thirty-nine high-risk osteosarcoma patients had radiotherapy; 119 sites were irradiated. A median four sites were irradiated per patient (range 1–14). The median radiation dose and number of fractions of radiation was 30 Gy in 10 fractions (range 10–70 Gy in 4–35 fractions). Chemotherapy, most commonly ifosfamide or methotrexate, was used in 80% (100/119) radiotherapy courses. Of 38 painful sites, 29 had improvement (76%), 4 had no change (10%), and 5 had more pain (13%). Objective and potentially durable responses were documented using PET-CT and bone scans with persistent and sustained reduction of standard uptake values (SUVs; initial SUV of indication lesion 9.5 became
- Published
- 2008